Updates
** Shares of Neumora Therapeutics NMRA.O fall 11.2% to $1.35 premarket, set to break three-day winning streak
** Johnson & Johnson JNJ.N late on Thursday scrapped trials of a depression drug similar to NMRA's navacaprant, citing lack of sufficient efficacy
** Brokerage Stifel, which was one among six joint bookrunners of NMRA's IPO in 2023, cuts rating to "hold" from "buy"
** "We had always seen the success of aticaprant... as an important source of validation for the KORA mechanism," says Stifel, referring to class of drugs known as KOR antagonists
** NMRA stock plunged about 80% in early January after experimental drug navacaprant flunked late-stage trial in depression patients
** Shares down about 90% since IPO in September 2023
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.